Takeda S, Namisaki T, Koizumi A, Takaya H, et al. The Macrophage Activation Marker Soluble CD163 Predicts the Response to Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma. Anticancer Res 2025;45:4493-4507.
PMID: 41006032